Eidos Therapeutics, Inc. EIDX
We take great care to ensure that the data presented and summarized in this overview for Eidos Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in EIDX
Top Purchases
Top Sells
About EIDX
Insider Transactions at EIDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2021
|
Uma Sinha Chief Scientific Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
303,525
-100.0%
|
-
|
|
Jan 26
2021
|
Cameron Turtle Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
50,699
-100.0%
|
-
|
|
Jan 26
2021
|
Jonathan C Fox Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
380,467
-100.0%
|
-
|
|
Jan 26
2021
|
Bridge Bio Pharma, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
14,428,836
+99.99%
|
-
|
|
Jan 13
2021
|
Uma Sinha Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-0.53%
|
$1,230,000
$123.89 P/Share
|
|
Jan 12
2021
|
Franco Valle Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,747
-100.0%
|
$218,375
$125.44 P/Share
|
|
Jan 12
2021
|
Franco Valle Senior Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
1,747
+50.0%
|
$12,229
$7.24 P/Share
|
|
Jan 11
2021
|
Franco Valle Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,500
-100.0%
|
$187,500
$125.61 P/Share
|
|
Jan 11
2021
|
Franco Valle Senior Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$10,500
$7.24 P/Share
|
|
Dec 28
2020
|
Jonathan C Fox Officer |
SELL
Bona fide gift
|
Direct |
500
-0.13%
|
-
|
|
Dec 15
2020
|
Cameron Turtle Chief Business Officer |
SELL
Open market or private sale
|
Direct |
26,294
-9.8%
|
$2,918,634
$111.69 P/Share
|
|
Dec 15
2020
|
Cameron Turtle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,294
+14.8%
|
$394,410
$15.1 P/Share
|
|
Dec 02
2020
|
Uma Sinha Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.39%
|
$455,000
$91.28 P/Share
|
|
Nov 11
2020
|
Cameron Turtle Chief Business Officer |
SELL
Bona fide gift
|
Direct |
1,500
-2.88%
|
-
|
|
Nov 11
2020
|
Cameron Turtle Chief Business Officer |
SELL
Open market or private sale
|
Direct |
13,410
-7.16%
|
$992,340
$74.51 P/Share
|
|
Nov 09
2020
|
Franco Valle Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,623
-100.0%
|
$120,102
$74.93 P/Share
|
|
Nov 09
2020
|
Franco Valle Senior Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
1,623
+50.0%
|
$11,361
$7.24 P/Share
|
|
Nov 02
2020
|
Cameron Turtle Chief Business Officer |
SELL
Open market or private sale
|
Direct |
12,500
-5.53%
|
$887,500
$71.32 P/Share
|
|
Nov 02
2020
|
Cameron Turtle Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.66%
|
$112,500
$15.1 P/Share
|
|
Oct 29
2020
|
Uma Sinha Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-0.77%
|
$360,000
$72.25 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders